Abstract
EBV-associated lymphomas are immune-related diseases arising from B-cell and T/NK cells. In cases where immune deficiency has been implicated in lymphomagenesis, reconstitution of immune system should be the first step. In cases that may require systemic therapy, immune checkpoint inhibitors, in particular PD1/PD-L1 inhibitors, can produce excellent clinical responses. Many EBV-targeting cell therapies are under active investigation.
| Original language | English |
|---|---|
| Title of host publication | Precision Cancer Therapies |
| Subtitle of host publication | Volume 2: Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practice |
| Publisher | wiley |
| Pages | 246-256 |
| Number of pages | 11 |
| ISBN (Electronic) | 9781119824572 |
| ISBN (Print) | 9781119824541 |
| DOIs | |
| State | Published - 1 Jan 2024 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- cellular therapy
- EBV driven lymphoid malignancies
- immune checkpoint inhibitors
- immunologic therapy
- lytic induction therapy
Fingerprint
Dive into the research topics of 'Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver